Literature DB >> 12734267

O-antigen serotypes and type III secretory toxins in clinical isolates of Pseudomonas aeruginosa.

Karine Faure1, David Shimabukuro, Temitayo Ajayi, Leonard R Allmond, Teiji Sawa, Jeanine P Wiener-Kronish.   

Abstract

The association of O-antigen serotypes with type III secretory toxins was analyzed in 99 clinical isolates of Pseudomonas aeruginosa. Isolates secreting ExoU were frequently serotyped as O11, but none were serotype O1. Most of the isolates that were nontypeable for O antigen did not secrete type III secretory toxins.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12734267      PMCID： PMC154700          DOI： 10.1128/JCM.41.5.2158-2160.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  33 in total

1.  Antibiotic resistance and virulence properties of Pseudomonas aeruginosa strains from mechanically ventilated patients with pneumonia in intensive care units: comparison with imipenem-resistant extra-respiratory tract isolates from uninfected patients.

Authors:  Patrick Di Martino; Hélène Gagnière; Hugues Berry; Laurent Bret
Journal:  Microbes Infect       Date:  2002-05       Impact factor: 2.700

2.  Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia.

Authors:  K Kurahashi; O Kajikawa; T Sawa; M Ohara; M A Gropper; D W Frank; T R Martin; J P Wiener-Kronish
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

3.  Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections.

Authors:  A Roy-Burman; R H Savel; S Racine; B L Swanson; N S Revadigar; J Fujimoto; T Sawa; D W Frank; J P Wiener-Kronish
Journal:  J Infect Dis       Date:  2001-05-17       Impact factor: 5.226

4.  Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

Authors:  Alan R Hauser; Enesha Cobb; Maria Bodi; Dolors Mariscal; Jordi Vallés; Joanne N Engel; Jordi Rello
Journal:  Crit Care Med       Date:  2002-03       Impact factor: 7.598

5.  Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa.

Authors:  Heather Feltman; Grant Schulert; Salman Khan; Manu Jain; Lance Peterson; Alan R Hauser
Journal:  Microbiology       Date:  2001-10       Impact factor: 2.777

6.  Production of exoenzyme S during Pseudomonas aeruginosa infections of burned mice.

Authors:  M J Bjorn; O R Pavlovskis; M R Thompson; B H Iglewski
Journal:  Infect Immun       Date:  1979-06       Impact factor: 3.441

Review 7.  Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa.

Authors:  H L Rocchetta; L L Burrows; J S Lam
Journal:  Microbiol Mol Biol Rev       Date:  1999-09       Impact factor: 11.056

8.  Hospital outbreaks caused by Pseudomonas aeruginosa: importance of serogroup O11.

Authors:  J J Farmer; R A Weinstein; C H Zierdt; C D Brokopp
Journal:  J Clin Microbiol       Date:  1982-08       Impact factor: 5.948

9.  The contribution of exoproducts to virulence of Pseudomonas aeruginosa.

Authors:  T I Nicas; B H Iglewski
Journal:  Can J Microbiol       Date:  1985-04       Impact factor: 3.226

10.  Contribution of exoenzyme S to the virulence of Pseudomonas aeruginosa.

Authors:  T I Nicas; B H Iglewski
Journal:  Antibiot Chemother (1971)       Date:  1985
View more
  20 in total

1.  Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.

Authors:  Raúl Recio; Mikel Mancheño; Esther Viedma; Jennifer Villa; María Ángeles Orellana; Jaime Lora-Tamayo; Fernando Chaves
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia.

Authors:  Y-A Que; H Lazar; M Wolff; B François; P-F Laterre; E Mercier; J Garbino; J-L Pagani; J-P Revelly; E Mus; A Perez; M Tamm; J-J Rouby; Q Lu; J Chastre; P Eggimann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-24       Impact factor: 3.267

3.  Spread of multidrug-resistant Pseudomonas aeruginosa clones in a university hospital.

Authors:  Maria Koutsogiannou; Eleanna Drougka; Apostolos Liakopoulos; Eleni Jelastopulu; Efthimia Petinaki; Evangelos D Anastassiou; Iris Spiliopoulou; Myrto Christofidou
Journal:  J Clin Microbiol       Date:  2012-12-12       Impact factor: 5.948

4.  Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.

Authors:  Akinobu Kamei; Yamara S Coutinho-Sledge; Joanna B Goldberg; Gregory P Priebe; Gerald B Pier
Journal:  Infect Immun       Date:  2010-12-13       Impact factor: 3.441

5.  Pseudomonas aeruginosa: so many virulence factors, so little time.

Authors:  Alan R Hauser
Journal:  Crit Care Med       Date:  2011-09       Impact factor: 7.598

6.  Acquisition and evolution of the exoU locus in Pseudomonas aeruginosa.

Authors:  Bridget R Kulasekara; Hemantha D Kulasekara; Matthew C Wolfgang; Lisa Stevens; Dara W Frank; Stephen Lory
Journal:  J Bacteriol       Date:  2006-06       Impact factor: 3.490

Review 7.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

8.  Identification of the mutation responsible for the temperature-sensitive lipopolysaccharide O-antigen defect in the Pseudomonas aeruginosa cystic fibrosis isolate 2192.

Authors:  Michael R Davis; Artur Muszynski; Ivonne V Lollett; Christopher L Pritchett; Russell W Carlson; Joanna B Goldberg
Journal:  J Bacteriol       Date:  2013-01-25       Impact factor: 3.490

9.  Vaccination against Pseudomonas aeruginosa pneumonia in immunocompromised mice.

Authors:  Jennifer M Scarff; Joanna B Goldberg
Journal:  Clin Vaccine Immunol       Date:  2007-12-19

10.  Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections.

Authors:  Antonio DiGiandomenico; Jayasimha Rao; Katie Harcher; Tanweer S Zaidi; Jason Gardner; Alice N Neely; Gerald B Pier; Joanna B Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.